A claim circulates widely on social media. The claim: these agents raise fat mobilisation four to sixfold. You'll see that figure, or something like it, repeated constantly. No study supports it, and the human literature points the other way. Under a pancreatic clamp, physiological hyperglucagonemia produced no significant change in fatty-acid flux (Jensen et al., 1991). Using microdialysis directly in human fat tissue, neither glucagon nor GLP-1 changed lipolysis, while isoprenaline, tested through the same catheter, raised it 249% (Bertin et al., 2001). The strongest positive result found was about a 40% rise, not 400–600% (Carlson et al., 1993). A review of the field says the extent of glucagon's effect on human fat tissue is controversial, and that glucagon acts primarily on the liver (Galsgaard et al., 2019). And there is a twist. In human fat cells, a triple agonist raised glycerol release by 28%, GIP alone raised it by 13%, and glucagon alone did nothing. The effect tracked GIP receptors, not glucagon receptors (Brachs et al., 2025). (R§53) So the mechanism usually described may be pointed at the wrong receptor entirely. What survives. The gate and the small liver door. Those rest on separate evidence. What changes is the story about how forcing goes wrong. It looks like a liver-side problem, not a four-fold surge of fat out of your fat cells. Now the second half, which I believe matters more. At monitored, titrated, therapeutic doses, they lower liver fat. They don't raise it. In a randomised, double-blind, placebo-controlled phase 2a trial, mean relative liver fat at 24 weeks fell by up to 82%. Placebo rose 0.3%. At the two highest doses, 79% and 86% of participants reached normal liver fat. On placebo, nobody did. (Sanyal et al., 2024, Nature Medicine; R§54) So the overflow picture is the signature of misuse. Maximal forcing driven into an already-loaded liver with no monitoring. It is not a property of the molecules used properly.